Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-To-Target Strategy for Rheumatoid Arthritis

ClinicoEconomics and Outcomes Research - New Zealand
doi 10.2147/ceor.s231558
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

FRI0754-HPR Impact of Corticosteroid Utilization on Biologic Disease-Modifying Antirheumatic Drug Initiation Among Patients With Rheumatoid Arthritis

2017English

Assessing the Effectiveness of Synthetic and Biologic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis &Ndash; A Systematic Review

Psoriasis: Targets and Therapy
DermatologyRheumatology
2015English

Determining a Low Disease Activity Threshold for Decision to Maintain Disease-Modifying Antirheumatic Drug Treatment Unchanged in Rheumatoid Arthritis Patients

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2009English

Predictors of Stopping and Starting Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis

Arthritis Care and Research
Rheumatology
2014English

Real-World Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany

Clinical Therapeutics
Pharmacology
2017English

Cost-Effectiveness of Combination Disease-Modifying Antirheumatics vs. Tumour Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: TACIT Trial

Arthritis Care and Research
Rheumatology
2020English

Lipid Profiles in Rheumatoid Arthritis Patients Treated With Disease-Modifying Antirheumatic Drugs

Reumatologia
RheumatologyAllergyImmunology
2014English

Safety, Cost and Effectiveness Issues With Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1999English

Comparative Effectiveness of Tocilizumab Versus TNF Inhibitors as Monotherapy or in Combination With Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis After the Use of at Least One Biologic Disease-Modifying Antirheumatic Drug: Analyses From the Pan-European TOCERRA Register Collaboration

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy